Drug Search Results
More Filters [+]

CEB-01

Alternative Names: CEB-01, CEB 01, CEB01
Latest Update: 2024-09-28
Latest Update Note: Clinical Trial Update

Product Description

CEB-01 is the first local control system for soft tissue sarcoma (STS) whose safety, tolerability and efficacy have been demonstrated and validated in regulatory preclinical studies. In addition, initial results from Phase I clinical development show that patients presented no toxicity or postoperative complications associated with CEB-01. (Sourced from: https://www.cebiotex.com/pipeline/)

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CEBIOTEX
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CEB-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title